Zalospirone

Zalospirone

SCHEMBL247563

O=C1[C@@H]2[C@@H]3C=C[C@@H]([C@H]4C=C[C@H]43)[C@@H]2C(=O)N1CCCCN1CCN(c2ncccn2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 2/20 0.72
HTR1A P08908 1/20 0.72
DRD4 P21917 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Zalospirone SCHEMBL247562 1.00 DRD2 (0.72) DRD2HTR1ADRD4
Zalospirone SCHEMBL17256233 1.00 DRD2 (0.72) DRD2HTR1ADRD4
Zalospirone SCHEMBL9526873 1.00 DRD2 (0.72) DRD2HTR1ADRD4
Zalospirone SCHEMBL13532604 1.00 DRD2 (0.72) DRD2HTR1ADRD4
Zalospirone SCHEMBL3374045 1.00 DRD2 (0.72) DRD2HTR1ADRD4
Zalospirone SCHEMBL123826 0.99 DRD2 (0.72) DRD2HTR1ADRD4
SCHEMBL9527393 0.91 DRD2 (0.71) DRD2HTR1ADRD4
SCHEMBL9528185 0.91 DRD2 (0.71) DRD2HTR1ADRD4
SCHEMBL17264052 0.91 DRD2 (0.71) DRD2HTR1ADRD4
SCHEMBL13534443 0.91 DRD2 (0.71) DRD2HTR1ADRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 873 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3154967-B1 PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES JOHNSON MATTHEY PLC (GB) 2020-07-29 EP claimed
CN-109745323-A Azapirone compound improves the active purposes of parasympathetic nerve 四川科瑞德制药股份有限公司 2019-05-14 CN claimed
US-20180099982-A1 PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES MACFARLAN SMITH LIMITED (GB) 2018-04-12 US claimed
EP-3154967-A1 PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES Johnson Matthey Public Limited Company (GB) 2017-04-19 EP claimed
CN-105636438-A Pharmaceutical composition comprising an AMPK activator and a serotonin active agent and uses thereof CHEN JIANHONG 2016-06-01 CN claimed
EP-2983473-A2 PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF ALS Mountain Llc (US) 2016-02-17 EP claimed
EP-2086544-B1 USE OF TESTOSTERONE AND A 5-HT1A AGONIST IN THE TREATMENT OF SEXUAL DYSFUNCTION EB IP LYBRIDOS B V (NL) 2015-12-23 EP claimed
WO-2015195478-A1 PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2015-12-23 WO claimed
US-20150361099-A1 PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES MACFARLAN SMITH LIMITED (GB) 2015-12-17 US claimed
US-20150328221-A1 COMPOUNDS FOR PROTECTION OF PHOTORECEPTOR CELLS AND FOR ENHANCING VISUAL FUNCTION UNDER LOW LIGHT CONDITIONS ALLERGAN INC (US) 2015-11-19 US claimed
US-6331536-B1 ADMINISTERING TO PATIENT IN NEED THEREOF EFFECTIVE AMOUNT OF SEROTONIN RECEPTOR ANTAGONIST TO PREVENT OR AMELIORATE SLEEP-RELATED BREATHING DISORDER THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2001-12-18 US claimed
US-6312717-B1 ANTIDEPRESSANTS OR ANTI ANXIETY BY ADMINISTERING AZAPIRONE AND 5-HT1A AUTOSOMAL RECEPTOR ANTAGONIST BRISTOL-MYERS SQUIBB COMPANY 2001-11-06 US claimed
EP-1066036-A1 AGENTS WITH SEROTONIN-RELATED ACTIVITY FOR THE TREATMENT FOR SLEEP APNEA THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2001-01-10 EP claimed
WO-2000006160-A1 TREATING DEPRESSION WITH A COMBINATION OF FLUOXETINE (PROZAC), PINDOLOL (VISKEN) AND BUSPIRONE (BUSPAR) SANOFI-SYNTHELABO (FR) 2000-02-10 WO claimed
WO-2000006163-A1 IMPROVED METHOD FOR TREATMENT OF SLEEP-RELATED RESPIRATORY DISORDERS BRISTOL-MYERS SQUIBB COMPANY (US) 2000-02-10 WO claimed
EP-0969842-A1 PHARMACEUTICAL COMPOSITION R.P. Scherer Limited (GB) 2000-01-12 EP claimed
WO-1999043319-A1 AGENTS WITH SEROTONIN-RELATED ACTIVITY FOR THE TREATMENT FOR SLEEP APNEA THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 1999-09-02 WO claimed
WO-1999013879-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING A MONOAMINE OXYDASE INHIBITOR AND THEIR USE IN THERAPY SANOFI-SYNTHELABO (FR) 1999-03-25 WO claimed
WO-1998042344-A1 PHARMACEUTICAL COMPOSITION R. P. SCHERER LIMITED (GB) 1998-10-01 WO claimed
WO-1997041878-A1 TREATMENT OF MOOD DISORDERS WITH A GROWTH HORMONE SECRETAGOGUE MERCK & CO., INC. (US) 1997-11-13 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180099982-A1 PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES NR5A2, NR4A3, NR4A2 DRD2 110/4885HTR1A 270/4885DRD4 51/4885
US-20150361099-A1 PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES NR5A2, NR4A3, NR4A2 DRD2 110/4885HTR1A 270/4885DRD4 51/4885
US-20150328221-A1 COMPOUNDS FOR PROTECTION OF PHOTORECEPTOR CELLS AND FOR ENHANCING VISUAL FUNCTION UNDER LOW LIGHT CONDITIONS NR2E3, GRK1, PDE6C DRD2 364/4885HTR1A 828/4885DRD4 585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.